rubitecan Report issue

Small molecule Experimental
AACT ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Rubitecan is an oral topoisomerase inhibitor, developed by SuperGen.   Wikipedia

Chemistry

  • SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C3N(Cc4cc5c(cccc5nc34)[N+](=O)[O-])C2=O
  • InChIKey: VHXNKPBCCMUMSW-FQEVSTJZSA-N
  • Mol. Mass: 393.36
  • ALogP: 1.99
  • ChEMBL Molecule:
    rubitecan  
More Chemistry

Pharmacology

Alternative names

9-nc | 9-nitro-20(s)-camptothecin | 9-nitrocamptothecin | 9-nitrocamptothecin, (s)-isomer | nitrocamptothecin | orathecin | rfs2000 | rfs 2000 | rfs-2000 | rubitecan

Organizations (11)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (21)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (21)


 

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Colorectal Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Gastrointestinal Stromal Tumors (Phase 2)

Hamartoma (Phase 2)

Intestinal Neoplasms (Phase 2)

Lung Diseases (Phase 2)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 2)

Sarcoma (Phase 2)

Stomach Neoplasms (Phase 2)

Urethral Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Uterus (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue